CTMX Q1 2025 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+22.8% YoY

Gross Profit

$51M100.0% margin

Operating Income

$23M44.4% margin

Net Income

$24M46.2% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

+33.7%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$98M

Total Liabilities

$73M

Stockholders' Equity

$25M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$41M	+22.8%
Gross Profit	$51M	$41M	+22.8%
Operating Income	$23M	$12M	+94.1%
Net Income	$24M	$14M	+70.6%

Revenue Segments

E G F R Products

$8M100%